Inhibition of IκB phosphorylation in cardiomyocytes attenuates myocardial ischemia/reperfusion injury

Onai, Yasuyuki; Suzuki, Jun–ichi; Kakuta, Tsunekazu; Maejima, Yasuhiro; Haraguchi, Go; Fukasawa, Hiroshi; Muto, Shoshi; Itai, Akiko; Isobe, Mitsuaki

doi:10.1016/j.cardiores.2004.03.002

Cited by 147 publications

(144 citation statements)

References 26 publications

Supporting

Mentioning

136

Contrasting

Unclassified

Order By: Relevance

“…The efficacy and pharmacological mechanism of IMD have been determined in previous studies (14,23,29). Moreover, drug safety of IMD up to 28 days also has been presented in a previous study (23). Vehicle (0.5% CMC) was used as a control.…”

Section: Methodsmentioning

confidence: 99%

“…After centrifugation, the second supernatant layer was collected for the analysis of heart protein. The separation of cytosolic and nuclear protein was carried out according to the previous study (10,23). Protein concentrations were measured with a Bio-Rad protein assay kit (Bio-Rad, Milan, Italy) to equalize the protein concentrations of all samples.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Inhibition of NF-κB improves left ventricular remodeling and cardiac dysfunction after myocardial infarction

Onai¹,

Suzuki²,

Maejima³

et al. 2007

American Journal of Physiology-Heart and Circulatory Physiology

109

View full text Add to dashboard Cite

August 18, 2006; doi:10.1152/ajpheart.00549.2006.-Several studies have demonstrated that NF-B is substantially involved in the progression of cardiac remodeling; however, it remains uncertain whether the continuous inhibition of NF-B is effective for the prevention of myocardial remodeling. Myocardial infarction (MI) was produced by ligation of the left anterior coronary artery of rats. IMD-0354 (10 mg/kg per day), a novel phosphorylation inhibitor of I B that acts via inhibition of IKK-␤, was injected intraperitoneally starting 24 h after induction of MI for 28 days. After 28 days, the IMD-0354-treated group showed significantly improved survival rate compared with that of the vehicle-treated group (P Ͻ 0.05). Although infarct size was similar in both groups, improved left ventricular (LV) remodeling and diastolic dysfunction, as indicated by smaller LV cavity (LV enddiastolic area: vehicle, 74.13 Ϯ 3.57 mm 2 ; IMD-0354, 55.00 Ϯ 3.73 mm 2 ; P Ͻ 0.05), smaller peak velocity of early-to-late filling wave (E/A) ratio (vehicle, 3.87 Ϯ 0.26; IMD-0354, 2.61 Ϯ 0.24; P Ͻ 0.05), and lower plasma brain natriuretic peptide level (vehicle, 167.63 Ϯ 14.87 pg/ml; IMD-0354, 110.75 Ϯ 6.41 pg/ml; P Ͻ 0.05), were observed in the IMD-0354-treated group. Moreover, fibrosis, accumulation of macrophages, and expression of several factors (transforming growth factor-␤1, monocyte chemoattractant protein-1, matrix metalloproteinase-9 and -2) in the noninfarcted myocardium was remarkably inhibited by IMD-0354. In conclusion, inhibition of NF-B activation may reduce the proinflammatory reactions and modulate the extracellular matrix and provide an effective approach to prevent adverse cardiac remodeling after MI. experimental heart failure; nuclear factor-b; matrix metalloproteinase; echocardiography MYOCARDIAL INFARCTION (MI) frequently leads to left ventricular (LV) dilatation and associated interstitial fibrosis in the noninfarcted myocardium. This adverse LV remodeling causes depressed cardiac performance and is an independent determinant of morbidity and mortality after MI (20). One of the recent conceptual advances in our understanding of the pathogenesis of LV remodeling is that this process is driven by the overexpression of various factors, including proinflammatory cytokines, angiotensin II, and norepinephrine, which have direct pathophysiological effects on cardiac myocytes, noncardiac myocytes, and the extracellular matrix (20). Although the expression of proinflammatory cytokines may be involved in wound healing after MI, it is believed that the overexpression of cytokines damages cardiac tissue and evokes excess deposition of fibrotic components, even in the noninfarcted myocardium.Several recent studies reported that nuclear factor-B (NF-B) is involved in the pathogenesis of heart failure (7, 35). Activation of NF-B induces activation of genetic programs that lead to transactivation of cytokines, chemokines, and matrix metalloproteinases (MMPs), promoting inflammatory and fibrotic responses that participate in the progre...

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Inhibition of NF-κB improves left ventricular remodeling and cardiac dysfunction after myocardial infarction

Onai¹,

Suzuki²,

Maejima³

et al. 2007

American Journal of Physiology-Heart and Circulatory Physiology

109

View full text Add to dashboard Cite

show abstract

“…The area stained blue in the noninfarcted region (at the mid-portion of the LV septum) was measured to evaluate the area of myocardial fibrosis using computerassisted analysis (Scion Image b4.0.2) at a magnification of Â 200 (ref. 14). Myocyte cross-sectional area was measured from images captured from wheat germ agglutinin (WGA) stained sections.…”

Section: Histological Examinationmentioning

confidence: 99%

“…After centrifugation, the supernatants were collected. MMP activity was measured by in-gel zymography with gelatin (1 mg/ml, type A from porcine skin; Sigma Chemical, St Louis, MO, USA) as the substrate, as described previously, 14 with enzyme activity attributable to MMP-9 and MMP-2 being visualized as clear bands against a blue background. Recombinant human MMP-9 and MMP-2 (Biomol, Plymouth Meeting, PA, USA) were included in the gels as standards.…”

Section: Gelatin Zymographymentioning

confidence: 99%

Telmisartan, a unique ARB, improves left ventricular remodeling of infarcted heart by activating PPAR gamma

Maejima

Okada

Haraguchi

et al. 2011

Laboratory Investigation

View full text Add to dashboard Cite

Unfavorable left ventricular (LV) remodeling after myocardial infarction (MI) leads to cardiac dysfunction. We examined whether Telmisartan, an angiotensin (Ang) II type I receptor blocker (ARB), could improve the recovery of LV function in a rat model of MI. The effect of Telmisartan as a peroxisome proliferator-activated receptor-g (PPAR-g) agonist was also investigated. After 28 days of MI, a significant improvement of survival was observed in the Telmisartan-treated rat group compared with the vehicle control rat group, non-PPAR-g agonistic ARB (Losartan)-treated rat group, and Telmisartan plus specific PPAR-g antagonist (GW9662)-treated rat group. Although no significant differences of blood pressure or infarct size were observed among these four groups, the Telmisartan group had better systolic and diastolic LV function. There was a significant reduction of the plasma brain natriuretic peptide level, cardiac fibrosis area, infiltration of macrophages, size of cardiomyocytes, terminal deoxynucleotidyl transferase dUTP nick end labeling-positive myocytes, activation of matrix metalloproteinases-2 and -9 (MMPs-2/9), and expression of transforming growth factor b-1 (TGF-b1), connective tissue growth factor (CTGF), and osteopontin (OPN), while expression of PPAR-g and activation of tissue inhibitor of metalloproteinase-1 (TIMP-1) was enhanced, in the noninfarcted myocardium of rats from the Telmisartan group compared with the other three groups. To mimic ischemic conditions in vitro, neonatal rat cardiomyocytes and cardiac fibroblasts were incubated in hypoxic condition for 24 h. Increased transcriptional activation of PPAR-g and TIMP-1, and inhibition of TGF-b1 expression were observed in cardiomyocytes, while decreased activation of MMPs-2/9 and decrease in CTGF and OPN expression was seen in cardiac fibroblasts cultured with Telmisartan. In conclusion, Telmisartan prevented unfavorable cardiac remodeling through a reduction of cardiac hypertrophy and fibrosis. An anti-inflammatory effect and PPAR-g activation were suggested to be important in addition to suppression of Ang II activity. Unfavorable left ventricular (LV) remodeling after myocardial infarction (MI) is characterized by hypertrophy associated with interstitial fibrosis of the noninfarcted myocardium, and causes LV dilatation and cardiac dysfunction. It is known that angiotensin II (Ang II) has a crucial role in the development of unfavorable LV remodeling, and recent studies based on animal experiments have demonstrated that treatment with an Ang-converting enzyme inhibitor (ACE-I) and/or Ang II type I receptor blocker (ARB) can attenuate unfavorable LV remodeling. 1,2 Moreover, other experimental studies suggested that activation of peroxisome proliferator-activated receptor-g (PPAR-g), a transcription factor, improves unfavorable LV remodeling after MI. [3][4][5] PPAR-g agonists not only regulate insulin sensitivity, but also have an anti-inflammatory effect by inhibiting the expression of adhesion molecules, cytokines, and chemokines, as well ...

show abstract

“…S2A in the supplemental material). IKK2 inhibitor V is known to selectively block IB␣ phosphorylation and prevent NF-B p65 nuclear translocation (22,34). TGF-␤1-induced production of ZEBRA in Mutu-I, Kem-I, and Sav-I cells was reduced by treatment with this inhibitor in a dose-dependent manner (Fig.…”

Section: Vol 85 2011 Tgf-␤1-mediated Pathway and Ebv Lytic Cycle Inmentioning

confidence: 92%

NF-κB-Mediated Modulation of Inducible Nitric Oxide Synthase Activity Controls Induction of the Epstein-Barr Virus Productive Cycle by Transforming Growth Factor Beta 1

Oussaief

Ramirez

Hippocrate

et al. 2011

J Virol

View full text Add to dashboard Cite

Transforming growth factor beta 1 (TGF-␤1) signal transduction has been implicated in many secondmessenger pathways, including the NF-B pathway. We provide evidence of a novel TGF-␤1-mediated pathway that leads to extracellular signal-regulated kinase (ERK) 1/2 phosphorylation, which in turn induces expression of an Epstein-Barr virus (EBV) protein, ZEBRA, that is responsible for the induction of the viral lytic cycle. This pathway includes two unexpected steps, both of which are required to control ERK 1/2 phosphorylation: first, a quick and transient activation of NF-B, and second, downregulation of inducible nitric oxide synthase (iNOS) activity that requires the participation of NF-B activity. Although necessary, NF-B alone is not sufficient to produce downregulation of iNOS, suggesting that another uncharacterized event(s) is involved in this pathway. Dissection of the steps involved in the switch from the EBV latent cycle to the lytic cycle will be important to understand how virus-host relationships modulate the innate immune system.

show abstract

Inhibition of IκB phosphorylation in cardiomyocytes attenuates myocardial ischemia/reperfusion injury

Cited by 147 publications

References 26 publications

Inhibition of NF-κB improves left ventricular remodeling and cardiac dysfunction after myocardial infarction

Inhibition of NF-κB improves left ventricular remodeling and cardiac dysfunction after myocardial infarction

Telmisartan, a unique ARB, improves left ventricular remodeling of infarcted heart by activating PPAR gamma

NF-κB-Mediated Modulation of Inducible Nitric Oxide Synthase Activity Controls Induction of the Epstein-Barr Virus Productive Cycle by Transforming Growth Factor Beta 1

Contact Info

Product

Resources

About